Blaze Bioscience Inc. Announces Presentation At GAC-SC 2015 Conference

Tumor Paint BLZ-100 results from first-in-human study in patients with skin cancer

SEATTLE & BRISBANE, Australia--(BUSINESS WIRE)--Blaze Bioscience, the Tumor Paint Company^®, a biotechnology company focused on guided cancer therapy, and its subsidiary, Blaze Bioscience Australia Pty Ltd, announced today that clinical data from the company’s Phase 1 study of Tumor Paint BLZ-100 in skin cancer will be presented at the 2015 2nd Global Advances and Controversies in Skin Cancer (GAC-SC) Conference, taking place in Brisbane, Australia on October 29-31, 2015.

“The successful completion of our first-in-human study of BLZ-100 provided key findings that are guiding our clinical development program in solid tumors”

The presentation, titled “Phase 1 First in Human Safety and Imaging Study of BLZ-100 in Subjects with Skin Cancer,” will be presented by Dr. Jesse Johnston of Veracity Clinical Research on behalf of Dr. Lynda Spelman, the Principal Investigator of the study.

“The successful completion of our first-in-human study of BLZ-100 provided key findings that are guiding our clinical development program in solid tumors,” said Dennis Miller, Blaze Bioscience Senior Vice President of Development. “With the rapid advancement of Tumor Paint BLZ-100, we are continuing to demonstrate clinical proof of concept in multiple clinical settings, including brain cancer.”

Details of the presentation are as follows:
Date: Friday, October 30, 2015
Time: 10:30 – 12:00pm AEST (Australian Eastern Time Zone)
Location: Brisbane Convention and Exhibition Centre, Room B3
Poster Number: 324b

About BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, colorectal, sarcoma, and skin cancer. More details about on-going trials are available at www.blazebioscience.com or www.clinicaltrials.gov.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former member of the executive management team at ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide-based therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop products based on knottin peptides as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptides for therapeutic and imaging applications. Blaze Bioscience Australia Pty Ltd is a wholly-owned subsidiary of Blaze Bioscience, Inc. For additional information, please visit www.blazebioscience.com.